Trial · NCT00001259
Participant flow112
How many started, completed or left each group, period by period.
1 to 20 of 112
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Study 1 | STARTED | Study 1, Phase 1, Assignment 1 - Placebo | 10 | |
| Study 1 | STARTED | Study 1, Phase 1, Assignment 2 - GnRH Agonist Injections (Lupron-L Only) | 10 | |
| Study 1 | STARTED | Study 1, Phase 2, Arm 1 - Estradiol, Then Progesterone | 0 | |
| Study 1 | STARTED | Study 1, Phase 2, Arm 2 - Progesterone, Then Estradiol | 0 | |
| Study 1 | STARTED | Study 2, Phase 1 - GnRH Agonist Injections (Lupron-L Only) | 0 | |
| Study 1 | STARTED | Study 2, Phase 2, Arm 1 - Estradiol, Then Progesterone | 0 | |
| Study 1 | STARTED | Study 2, Phase 2, Arm 2 - Progesterone, Then Estradiol | 0 | |
| Study 1 | Completed Phase 1 | Study 1, Phase 1, Assignment 1 - Placebo | 10 | |
| Study 1 | Completed Phase 1 | Study 1, Phase 1, Assignment 2 - GnRH Agonist Injections (Lupron-L Only) | 10 | |
| Study 1 | Completed Phase 1 | Study 1, Phase 2, Arm 1 - Estradiol, Then Progesterone | 0 | |
| Study 1 | Completed Phase 1 | Study 1, Phase 2, Arm 2 - Progesterone, Then Estradiol | 0 | |
| Study 1 | Completed Phase 1 | Study 2, Phase 1 - GnRH Agonist Injections (Lupron-L Only) | 0 | |
| Study 1 | Completed Phase 1 | Study 2, Phase 2, Arm 1 - Estradiol, Then Progesterone | 0 | |
| Study 1 | Completed Phase 1 | Study 2, Phase 2, Arm 2 - Progesterone, Then Estradiol | 0 | |
| Study 1 | Started Phase 2 | Study 1, Phase 1, Assignment 1 - Placebo | 0 | |
| Study 1 | Started Phase 2 | Study 1, Phase 1, Assignment 2 - GnRH Agonist Injections (Lupron-L Only) | 0 | |
| Study 1 | Started Phase 2 | Study 1, Phase 2, Arm 1 - Estradiol, Then Progesterone | 4 | |
| Study 1 | Started Phase 2 | Study 1, Phase 2, Arm 2 - Progesterone, Then Estradiol | 6 | |
| Study 1 | Started Phase 2 | Study 2, Phase 1 - GnRH Agonist Injections (Lupron-L Only) | 0 | |
| Study 1 | Started Phase 2 | Study 2, Phase 2, Arm 1 - Estradiol, Then Progesterone | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00001259/flow